Novel site-specific mast cell subpopulations in the human lung

C K Andersson,1,2 M Mori,1,2 L Bjermer,1 C-G Löfdahl,1 J S Erjefält1,2

ABSTRACT

Background: Lung mast cells are stereotypically divided into connective tissue (MC TC) and mucosal (MC T) mast cells. This study tests the hypothesis that each of these subtypes can be divided further into site-specific populations created by the microenvironment within each anatomical lung compartment.

Methods: Surgical resections and bronchial and transbronchial biopsies from non-smoking individuals were obtained to study mast cells under non-inflamed conditions. Morphometric and molecular characteristics of mast cell populations were investigated in multiple lung structures by immunohistochemistry and electron microscopy.

Results: MC T and MC TC coexisted in all compartments, with MC T being the prevailing type in bronchi, bronchioles and the alveolar parenchyma and MC TC being more abundant in pulmonary vessels and the pleura. Each of the MC TC and MC T phenotypes could be further differentiated into site-specific populations. MC TC were significantly larger in pulmonary vessels than in small airway walls, while the reverse was observed for MC T. Within each MC TC and MC T population there were also distinct site-specific expression patterns of the IgE receptor, interleukin-9 receptor, renin, histidine decarboxylase, vascular endothelial growth factor, fibroblast growth factor, 5-lipoxygenase and leukotriene C4 synthase (eg, bronchial MC TC consistently expressed more histidine decarboxylase than alveolar MC TC). Renin content was high in vascular MC TC but markedly lower in MC TC in other compartments. For both MC TC and MC T, the IgE receptor was highly expressed in conducting airways but virtually absent in alveolar parenchyma.

Conclusions: These findings demonstrate novel site-specific subpopulations of lung MC TC and MC T at baseline conditions. This observation may have important implications in the future exploration of mast cells in a number of pulmonary diseases.

Mast cells are multipotent cells that originate in the bone marrow and home into tissues of many organs including the lung.1–3 They are intimately linked with allergy and have established roles in allergic rhinitis and asthma where they have been extensively studied in upper and central airways, respectively.3–5 Less is known about mast cells in more peripheral airways.

Both small airways and the alveolar parenchyma contain significant numbers of mast cells. In recent years they have been ascribed expanding roles in innate immunity, pathogen recognition, remodeling and vascular regulation,6–9 suggesting their involvement in a number of non-allergic respiratory diseases such as chronic obstructive pulmonary disease (COPD), interstitial pulmonary fibrosis and pulmonary infections. In vivo data on human lung mast cells—particularly in peripheral regions—have, however, remained scarce. Most previous functional in vivo data come from rodents, including genetically modified mice. However, apart from translational difficulties between animal models and human disease,7 mice lack mast cells in small airways and the alveolar region. Human lung mast cell populations cannot be adequately mimicked in murine models and must therefore be studied directly in man. However, the progress has been hampered by the heterogeneity of mast cells in humans.2,10

Mast cell heterogeneity, which has mainly been studied in rodents, involves differences in morphology, mediator content and histochemical characteristics as well as response to external stimuli.11–12 Determination of the granule content of tryptase and chymase was used to identify the so-called mucosal mast cells (MC T) and connective tissue mast cells (MC TC), a division that emerged as robust and became the common classification of mast cell subtypes in man.13 This classification has also remained the archetypical division in the many papers on mast cell populations in respiratory diseases.12–15 Importantly, although MC T is the dominant type in most parts of the lung, the relative proportion and distribution of MC T and MC TC changes with disease,16 with potential clinical consequences.14–17

There are indications that the division into MC T and MC TC does not adequately explain the complexity of lung mast cell heterogeneity. It is well known that the phenotype of any mast cell is highly dependent on the local microenvironment.3 Likewise, it is known that, in healthy baseline conditions, both MC T and MC TC populations are present in all anatomical compartments of the lung. Based on these notions, we hypothesised that, in the anatomical compartments of the lung, there is a site-specific heterogeneity that is present under non-inflamed healthy conditions and goes beyond the MC T and MC TC classification. This study explores this possibility by detailed assessments of morphometric and molecular characteristics of lung tissue mast cell populations under baseline conditions.

METHODS

Human lung tissues

Tissue was obtained from lung lobectomy samples resected from patients undergoing surgery for suspected lung cancer at the University Hospital in Lund, Sweden, in otherwise healthy non-smoking individuals. Lung tissue samples were collected during a period of 5 years from April 2001...
to April 2006. Only patients with solid well-delineated tumours were included, and tissue samples were obtained at a distance from the tumour. This procedure has commonly been used to collect human control tissue.\textsuperscript{18} 19 From each patient, multiple large tissue blocks representing the major anatomical regions of the lung were selected for histological analysis (table 1). Central airways (bronchi), small airways (bronchioles; defined by an absence of cartilage and <2 mm in diameter), pulmonary vessels and alveolar parenchyma were included in the analysis.

As additional control tissue, we also collected bronchial and transbronchial biopsy specimens from young healthy non-atopic individuals (table 2, see also online supplement) during a study period from May 2007 to February 2008 at the Department of Respiratory Medicine, Lund University Hospital.

Bronchoscopy was performed after local anaesthesia with a flexible bronchoscope (Olympus IT160, Tokyo, Japan) and transbronchial biopsy specimens were taken with biopsy forceps (Olympus FB211D) under fluoroscopic guidance in the peripheral right lower lobe at a distance of ≥2 cm from the chest wall. Before bronchoscopy the subjects received oral midazolam (1 mg/10 kg) and intravenous glycopyrronium (0.4 mg). Local anaesthesia was given as lidocaine spray, locally and through a spray catheter. Just before the procedure, alphentanyl 0.1–0.2 mg/10 kg was given intravenously when needed. Central airway biopsy specimens (n = 5) were taken from the segmental or subsegmental carina in the right lower and upper lobes, followed by transbronchial biopsy specimens (n = 5) in the right lower lobe. Oxygen was given as needed during and after the procedure. Fluoroscopy of the right lung was performed immediately and 2 h after the procedure to rule out significant bleeding or pneumothorax. Betametasone 3–4 mg was given to prevent fever reactions and the subject was discharged after 2 h of observation.

### Table 1: List of primary antibodies for mast cell-related molecules with dilution, clone, manufacturer and secondary antibody

<table>
<thead>
<tr>
<th>Primary antibody</th>
<th>Dilution</th>
<th>Antigen retrieval pretreatment</th>
<th>Clone and manufacturer</th>
<th>Secondary antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoclonal mouse anti-tryptase/AP</td>
<td>1:3000</td>
<td>–</td>
<td>MAB1222A (Chemicon; Temecula, California, USA)</td>
<td>–</td>
</tr>
<tr>
<td>Monoclonal mouse anti-chymase</td>
<td>1:100</td>
<td>MW citrate pH6</td>
<td>CC1 (NovoCastra; Newcastle-upon-Tyne, UK)</td>
<td>HRP-conjugated goat anti-mouse (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Monoclonal mouse anti-interleukin 9 receptor</td>
<td>1:30</td>
<td>MW citrate pH 6</td>
<td>CD129, AHER (BioLegends; San Diego, California, USA)</td>
<td>Horse anti-mouse IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Polyclonal rabbit anti-VEGF</td>
<td>1:50</td>
<td>MW citrate pH 6</td>
<td>A-20 sc-152 (Santa Cruz, California, USA)</td>
<td>Goat anti-rabbit IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Polyclonal goat anti-5-LD</td>
<td>1:50</td>
<td>MW citrate pH 6</td>
<td>N-19 sc-8885 (Santa Cruz, California, USA)</td>
<td>Donkey anti-goat IgG*, 1:100, 705-066-147 (Jackson ImmunoResearch; Suffolk, UK)</td>
</tr>
<tr>
<td>Polyclonal goat anti-LTC$_4$ synthase</td>
<td>1:200</td>
<td>MW citrate pH 6</td>
<td>S-18 sc-22564 (Santa Cruz, California, USA)</td>
<td>Donkey anti-goat IgG*, 1:100, 705-066-147 (Jackson ImmunoResearch; Suffolk, UK)</td>
</tr>
<tr>
<td>Polyclonal rabbit anti-IgER1A</td>
<td>1:50</td>
<td>MW S1700</td>
<td>10980-1-AP (Proteintech Group; Chicago, Illinois, USA)</td>
<td>Goat anti-rabbit IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Monoclonal mouse anti-renin</td>
<td>1:100</td>
<td>MW citrate pH 6</td>
<td>Swant Scientific (Bellinzona, Switzerland)</td>
<td>Horse anti-mouse IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Polyclonal rabbit anti-FGF-2</td>
<td>1:50</td>
<td>MW citrate pH 6</td>
<td>147 sc-7 (Santa Cruz, California, USA)</td>
<td>Goat anti-rabbit IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Polyclonal rabbit anti-HDC</td>
<td>1:50</td>
<td>MW citrate pH 6</td>
<td>Provided by Professor Lo Persson (Lund University)</td>
<td>Goat anti-rabbit IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
<tr>
<td>Polyclonal rabbit anti-c-kit</td>
<td>1:400</td>
<td>MW citrate pH 6</td>
<td>Dako (Glostrup, Denmark)</td>
<td>Goat anti-rabbit IgG*, 1:200 (Vector Laboratories; Burlingame, California, USA)</td>
</tr>
</tbody>
</table>

For antibody references see online supplement. High-temperature antigen unmasking techniques (microwave for 2 × 7 min, 800 W) were performed in citrate buffer pH 6 (Merck, Darmstadt, Germany) or S1700 (Dako, Glostrup, Denmark).

### Table 2: Subject characteristics and overview of tissue samples

<table>
<thead>
<tr>
<th>Variable</th>
<th>Lung resections</th>
<th>Bronchial biopsies</th>
<th>Transbronchial biopsies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>10</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td>Tissue block/biopsies</td>
<td>n = 28*</td>
<td>n = 26</td>
<td>n = 28</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>2/8</td>
<td>4/1</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.9 (33–76)</td>
<td>29.6 (25–41)</td>
<td></td>
</tr>
<tr>
<td>FEV$_1$ (% predicted)</td>
<td>110 (82–141)</td>
<td>107 (95–118)</td>
<td></td>
</tr>
<tr>
<td>Smoking (pack-years)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as median values (range). FEV$_1$, forced expiratory volume in 1 s.

*Each large tissue block from the resections was selected to represent the major anatomical lung compartments.

### Tissue processing and double immunohistochemical staining of MC$_T$ and MC$_{TC}$

Immediately after excision, samples for immunohistochemistry were placed in 4% buffered formaldehyde. After dehydration and paraffin embedding, a large number of 3 μm sequential sections were generated from each tissue block.

A double staining protocol was used for simultaneous visualisation of MC$_T$ and MC$_{TC}$ cells (see online supplement for details). Briefly, after rehydration and antigen retrieval, chymase-containing mast cells were detected by a primary anti-chymase antibody and a horseradish peroxidase-conjugated secondary antibody which was visualised using 3,3-diaminobenzidine as chromogen. Next, the remaining MC$_T$ subclass was visualised with an alkaline phosphatase-conjugated anti-tryptase antibody and the chromogen New-Fuchsins.

### Density, distribution and size analysis of MC$_T$ and MC$_{TC}$ populations

**Mast cell density**

In sections double stained for MC$_T$ and MC$_{TC}$, the density of each population was quantified manually and related to the tissue area which was determined in detail by a digital image algorithm that excluded any luminal spaces, notably also in the alveolar parenchyma (Image-Pro Plus, MediaCybernetics, Silver Spring, Maryland, USA and NIS-elements, Nikon, Melville, New York, USA).
Size and shape analysis
In each major compartment of the lung the mean cross-section of the MCT and MCCT was calculated. Cell size was measured with manual cursor tracing at high resolution digital images using software Image J (Version 1.34s; National Institutes of Health, USA). MCT and MCCT were visualised in the same section by double staining (see above). The size measurements used in the main study were performed on cross-sectional airways and pulmonary vessels. To exclude any misleading results from an uneven or biased sectional plane, we also analysed cell sizes in a large number of longitudinal sections of the airways and vessels.

To further improve our quantification of mast cell sizes, we employed a stereological approach using volume fraction measurements from a fixed cell number quantification. In short, using a point grid overlaid onto randomly orientated tissue sections, point counting was performed until a fixed number of mast cells (240/patient) had been hit by one or more points. With similar cell numbers analysed, differences in volume fraction will equate to differences in mean cell size.

The volume fraction for each mast cell subtype and compartment was calculated using the equation:

\[ V_{c} (MC, compartment) = \frac{\Sigma P (MCT, MCCT)}{\Sigma P (SA, PV)} \]

where P is points counted, SA denotes the small airways compartment and PV is pulmonary vessels. The cell shape was calculated using the formula:

circularity = 4\pi (area/perimeter^2)

Immunohistochemical identification of mast cell-related molecules
Triple staining with immunofluorescence was used to simultaneously visualise both MCCT and MCT populations together with the following mast cell-related molecules: IgE receptor (IgER1a), histidine decarboxylase (HDC), interleukin-9 receptor (IL9R), vascular endothelial growth factor (VEGF), 5 lipooxygenase (5-LO), leucotriene C4 synthase (LTC4-S), renin and fibroblast growth factor (FGF-2) (see online supplement and table 1 for protocol details). The markers were selected to represent multiple aspects of mast cell biology ranging from mast cell-promoting/survival factors (c-kit/CD117, IL9R), key activators (IgER1A), key enzymes used to produce mast cell-derived eicosanoids (LTC4-S and 5-LO) and histamine (HDC), as well as growth factors previously described in mast cells (eg, VEGF and FGF-2). After appropriate antigen retrieval, sections were stained for the molecule of interest using specific and validated primary antibodies (table 1) and visualised by an appropriate biotinylated secondary antibody and Alexa-Flour 555-conjugated streptavidin (Molecular Probes, Oregon, USA). Next, MCCT and MCT cells were stained with anti-tryptase and anti-chymase antibodies labelled with AlexaF-488 and AlexaF-350 fluorochromes, respectively (Zenon IgG labelling kit, Molecular Probes).

Transmission electron microscopy
From each lung compartment, separate glutaraldehyde/formaldehyde-fixed samples were processed and analysed by routine transmission electron microscopy using a standard protocol and a Philips CM-10 TEM microscope (Philips, Eindhoven, The Netherlands). Mast cell subtypes and ultrastructural signs of degranulation were analysed according to previously described ultrastructural criteria.

Quantifications and statistical analysis
For direct comparison of the lung compartments within each single section, the main quantifications were (if not stated otherwise) performed on large sections from the surgical material. For quantification of mast cell-related molecules and morphometric parameters, numerous mast cells were analysed in three separate tissue blocks from each patient selected to contain the major anatomical compartments. When possible, we also corroborated our findings in bronchial and transbronchial biopsy specimens from young healthy individuals.

Data were analysed statistically using the Mann–Whitney rank sum test for comparison between two groups when an overall significant difference was detected, and one-way ANOVA corrected for Bonferroni’s multiple comparison test for comparison between three groups or more using GraphPad Prism V.4.03 (GraphPad Software). Differences between groups were considered significant at p values of \(<0.05\).

RESULTS
MCT and MCCT are abundant at all airway levels with a gradual increase towards peripheral regions
Mast cells were abundant at all airway levels (figs 1A and 2A–E), with a gradual and statistically increased density towards the alveolar parenchyma (fig 1A). Mast cells were also abundant in the adventitial layer in pulmonary vessels and in the perivascular layer outside the adventitia (figs 1A and 2E), whereas the number

![Figure 1](http://thorax.bmj.com/)

**Figure 1** Mast cell (MC) density in healthy human lung. The density was significantly increased from the central to the distal airways. (A) Total mast cell density and the number of mucosal mast cells (MCc) and connective tissue mast cells (MCCT) per mm² lung tissue in central airways, small airways, alveolar parenchyma and the adventitia and perrivascular tissue of pulmonary vessels. (B) Proportion of each subtype (%) for each compartment. Data expressed as mean (SEM). *p<0.05 vs total mast cells in central airways. \( \dagger p<0.05, \ddagger p<0.01 \) vs MCc in pulmonary vessels. Statistical analyses were performed using the Mann-Whitney rank sum test.


299
in the pleural wall was modest (26.7 (5) cells/mm²). Similar mast cell densities were present in bronchial and transbronchial biopsies from young healthy controls.

Proportion and distribution of MC₁ and MC₉ₐ

Lung tissues double stained for MC₉ₐ and MC₁ showed that, in all major anatomical compartments except the adventitia of the pulmonary vessels, MC₁ was the predominant subtype (fig 1A, B). The proportion of MC₁ was highest in conducting airways, slightly increased in the alveolar parenchyma and significantly decreased in pulmonary vessels (fig 1B). MC₉ₐ were the most numerous subtype in the pleural wall, with 20.5 (7) cells/mm² compared with 6.2 (2) cells/mm² for MC₁ (p<0.001). Details of MC₉ₐ/MC₁ distribution within sub-compartments in conducting airways and vessels are presented in the online supplement.

MC₁ and MC₉ₐ may be divided into further site-specific subgroups

Differentially sized MC₁ and MC₉ₐ populations in distinct anatomical compartments

By measuring cell cross-section areas, it was found that the size within each of the MC₁ and MC₉ₐ population differed dramatically between anatomical regions (fig 3A). Large MC₁ cells were found in bronchi and small airways and significantly smaller MC₁ were present in pulmonary vessels (p<0.001). For MC₉ₐ the reverse pattern was found, with large MC₉ₐ in pulmonary vessel walls and a significantly smaller (p<0.001) MC₉ₐ population in bronchial and small airway walls (fig 3A). To exclude the possibility that the size differences were not caused by uneven tissue orientation in distinct MC populations, these differences were also present in longitudinal sections of airways and vessels (see online supplement). Distinct size changes were further corroborated by stereology, where distinct volume fractions were found after analysis of equal mast cell numbers. In small airways the volume fraction of MC₁ and MC₉ₐ was 0.027 (0.004) and 0.009 (0.0007), respectively (p<0.0005). For pulmonary vessels, the opposite was true; MC₁ had a smaller volume fraction per mast cell number than MC₉ₐ (0.009 (0.0008) vs 0.019 (0.002), p<0.002).

In alveolar regions, mast cells displayed a similar distribution as in conducting airways (ie, large MC₁ and smaller MC₉ₐ, fig 3A). The distinctly sized mast cell population was confirmed in all compartments after labelling with the mast cell surface marker c-kit (CD117).

Shape index

Calculating the circularity of MC₉ₐ and neighbouring MC₁ cells showed that MC₉ₐ cells were significantly more circular in...
Figure 3  Mast cell size and shape analysis in different lung compartments. (A) Size changes for mucosal mast cells (MC\textsubscript{T}) and connective tissue mast cells (MC\textsubscript{TC}) in central airways, small airways, alveolar parenchyma and pulmonary vessels. (B) Differences in shape (circularity) between and within MC\textsubscript{T} and MC\textsubscript{TC} in central airways, small airways and pulmonary vessels. No significant shape difference was found in alveolar parenchyma. The results are shown as scatterplot graphs where black bars indicate the mean values. (C–E) Representative micrographs showing examples of the variation in mast cell shapes, with two examples of highly irregular "dendritic" mast cells (C, D) and more circular types (E), stained for c-kit. (Bar = 10 \mu m). Statistical analyses in (A) and (B) were performed using the Mann-Whitney rank sum test when comparing two groups and one-way ANOVA corrected for Bonferroni’s multiple comparison test for comparison between three or more groups. Significant differences between MC\textsubscript{T} and MC\textsubscript{TC} in different compartments: *p<0.05, ***p<0.001. †††p<0.001 considered significant when comparing MC\textsubscript{size} between anatomical locations.

Figure 4  Summary of molecular staining patterns shown as relative expression (%) of mast cell-related molecules within (A) mucosal mast cells (MC\textsubscript{T}) and (B) connective tissue mast cells (MC\textsubscript{TC}) in different lung compartments. Proportion of total mast cells and MC\textsubscript{T} and MC\textsubscript{TC} subtypes staining positively for (C) IgE and (D) histidine decarboxylase (HDC). Data expressed as mean (SEM). *p<0.05, **p<0.01, ***p<0.001 compared with total mast cells in central airways. †p<0.05 compared with MC\textsubscript{T} in small airways. ††p<0.05, †††p<0.001 compared with MC\textsubscript{TC} in small airways. Statistical analyses were performed using the Mann–Whitney rank sum test.
all compartments (apart from the alveolar parenchyma) than neighbouring MCT cells in the bronchial wall (p = 0.008), small airways (p < 0.001) and pulmonary vessels (p = 0.004), fig 3B–E). Occasional MCT cells in bronchi and small airways had a dendritic morphology (fig 3C, D).

Confirmation of non-degranulating phenotypes by electron microscopy

Ultrastructural examination of MCTC and MCT subtypes, which were identified by their distinct granule morphology, revealed that, in all the compartments examined, mast cells were of a non-degranulating phenotype (ie, displaying filled granules lacking classical ultrastructural sign of, for example, anaphylactic or piecemeal degranulation).

Distinct expression of mast cell-related molecules in site-specific MCT and MCTC populations

Distinct differences within each MCT and MCTC population could be further corroborated by differential molecular expression of mast cell-related molecules (table 1, data summarised in fig 4A, B). Thus, apart from the expected differences between MCTC and MCT cells, our data showed numerous examples of site-specific expression patterns within each of the MCTC or MCT populations (figs 4–6).

MCTC

On the whole, alveolar MCTC had a low expression of the present set of mast cell-related molecules compared with, for example, vessel and airway MCTC. The populations of MCTC in bronchi, small airways and alveolar walls differed significantly in their expression of IgE (fig 4C). There was a significant and gradual decrease from an extensive IgE (71.2 (6)%), moderate in small airways (43.4 (10)%) to a virtually absence of expression in alveolar MCTC cells (fig 4B, C). A similar pattern was seen in bronchial and transbronchial biopsies from the young control population. The expression of HDC followed the same pattern as IgE. HDC expression significantly decreased from bronchi and small airways (60.6 (5)% and 65.5 (5)%, respectively) to the alveolar region (41.2 (3)%, p = 0.002, fig 4D). Renin, just recently discovered as an

Figure 5 Molecular expression pattern (%) of (A) interleukin-9 receptor (IL9R), (B) renin, (C) vascular endothelial growth factor (VEGF), (D) fibroblast growth factor-2 (FGF-2), (E) leukotriene C4 synthase (LTC4-S) and (F) 5-lipoxygenase (5-LO) in different compartments. Results are shown as the percentage of total mast cells (MCs) and MCT and MCTC subtypes positive for the respective mediators. Data expressed as mean (SEM). *p<0.05, **p<0.01, ***p<0.001 compared with total mast cells in central airways. ††p<0.01 compared with MCTC in small airways. ‡‡p<0.05, †††p<0.01 compared with MCTC in central airways. Statistical analyses were performed using the Mann–Whitney rank sum test.
Airway mast cell mediator, had significantly (p = 0.002) elevated expression in the large MC TC of pulmonary vessels (65.6 (7)% compared with the small-size MC TC populations found in other compartments of the lung (figs 4B and 5B). Notably, expression of the leukotriene-producing enzymes 5-LO and LTC4-S were mainly expressed in the MCTC populations of pulmonary vessels and small airways (figs 4B and 5E, F). For example, the expression of 5-LO in MCTC in small airways (86.8 (7)% and in pulmonary vessels (82.1 (14)% was increased compared with the central airways (15.6 (15)%), p = 0.017 and p = 0.03, respectively) or the alveolar parenchyma (12.8 (12.8)% p = 0.008 and p = 0.021, respectively). A similar heterogeneity was also observed for IL9R among the lung MCTC populations (figs 4B and 5A). Notably, as for renin, VEGF and FGF2 were absent from alveolar MC TC (fig 5C, D).

MC<sub>T</sub>

MC<sub>T</sub> also differed significantly in their expression pattern between the different parts of the lung. The proportion of MC<sub>T</sub> expressing IgE R1α was, like MC<sub>TG</sub>, highest in the bronchi (72.5 (7)%), significantly decreased in the small airways (43.0 (10)% p = 0.05) and virtually absent in the alveolar region (4.7 (2)% p = 0.002, fig 4A, C). The proportion of MC<sub>T</sub> expressing HDC also followed the pattern seen for MC<sub>TG</sub> with a decrease from the bronchi to the alveolar region (75.4 (2)% to 14.4 (4)% p = 0.004, fig 4D). Although renin was expressed in the central airways (21.4 (1)%), the proportions of renin-positive MC<sub>T</sub> were increased in more distal airways (small airways: 51.5 (10)% p = 0.05; alveolar region: 58.5 (9)% p = 0.006, fig 5B). A similar pattern was observed for 5-LO, with a low bronchial expression (10.1 (3)% compared with, for example, the small airways and pulmonary vessels (32.6 (7)% and 46.7 (15)% respectively; p = 0.0173, fig 5F). In contrast, LTC4-S was richly expressed in the central airways (53.4 (4)% fig 5E). Both FGF-2 and VEGF were abundantly expressed in the central airways and pulmonary vessels with only a moderate decrease in the small airways and alveolar tissue (fig 5C, D).
DISCUSSION

The phenomenon of mast cell heterogeneity has been known for decades and studied in several species. However, apart from the MC and MC classification, this phenomenon has remained poorly investigated, especially under human in vivo conditions. The present work describes a new level of heterogeneity by showing that, even under baseline conditions, each anatomical compartment of the lung contains distinct MC and MC populations. For example, the frequently studied and highly IgR1α-expressing MC population in the bronchi and small airways differs markedly—both in size and molecular content—from the less studied MC populations in alveoli or pulmonary vessels. Equally striking differences occurred between site-specific MC populations. These findings show that mast cells are exceedingly plastic cells with a baseline phenotype determined by the local tissue milieu.

The present type of novel heterogeneity has several practical implications. In agreement with previous studies, this report suggests that quantification of lung mast cells in disease without proper information of anatomical location or subtype may be misleading; a certain subtype in one location may display increased numbers and/or activation whereas the situation may be reversed in neighbouring areas. An additional aspect underscored by this study is the complexity in assessing lung-derived mast cells ex vivo. Indeed, from our data it can be expected that purification of mast cells from lung homogenates yield a mixture of several populations with potentially different propensity to survive and get activated ex vivo. This type of heterogeneity may account for the many previously reported discrepancies in functionality among lung-derived mast cells. In this context, knowledge about the present site-specific heterogeneity may be helpful if lung mast cells were instead purified from dissected well-defined compartments of the lung together with, for example, CD88-based separation of MC and MC populations.25

In this study mast cells were plentiful at all regions of the lung, and, consistent with other studies, MC was by far the most abundant subtype. Previous studies have shown an increase in mast cell density in small airways compared with bronchi. Much less is known regarding alveolar mast cells. Interestingly, in this study the alveolar lung parenchyma was the most mast cell-rich compartment. In light of this, the present novel finding of a paucity of IgR1α on alveolar mast cells is intriguing and suggests a reduced capacity for classical anaphylactic degranulation among alveolar mast cells. In agreement, Balzar et al report reduced IgE-bearing mast cells in the alveolar tissue of subjects with asthma and healthy controls.20 It seems rational to have mechanisms for local downregulation of FcεRI and thus prevent an anaphylactic degranulation in alveolar regions. Common effects of classical degranulation such as plasma extravasation would be a catastrophic event in the alveoli. It is therefore likely that alveolar mast cells are under strict regulation by non-IgE mast cell triggers such as C5aR and CD80L. Irrespective of the activation mechanism, alveolar mast cells are likely to have a variety of roles ranging from regulation of blood flow (supported by the high renin content in alveolar mast cells) to participation in the many new functions recently ascribed to mast cells ranging from immune modulators, effector cells in innate immunity to probiotic cells.22–20

Size differences between mast cell populations in vitro have been reported previously but no link has been made to an in vivo setting. Our extensive quantification of mast cell size, with data from both cross-sectioned and longitudinally-sectioned airways and vessels, would yield a fair estimation of the size of MC and MC since we did not assume the orientation, used randomly orientated tissues, counted nucleated cells only and counted all the mast cells in each structure analysed. Non-biased stereology is nevertheless the best approach for measuring cell density and size. However, many practical limitations exist in incorporating these methods into clinical studies owing, for example, to the limited quantity of tissue samples and because studies using human material cannot be completely designed to fulfil stereological criteria. The most correct way to measure individual cell size would be by the optical dissector method. However, this was not applicable with the double immunohistochemical staining of MC and MC populations used in this study. Taking advantage of the fact that the tissue blocks were randomly selected and orientated, we therefore applied the stereology “volume fraction” approach that confirmed our conventional cell area measurements.

The observation in this study of site-specific size differences among MC and MC populations represents an intriguing and novel finding. These differences were consistent regardless of whether the size determination was based on visualisation of granule proteins or surface markers. Any shape and size changes due to degranulation were ruled out since our electron microscopic analysis showed that the mast cells were resting, irrespective of their localisation. It is currently unknown how one part of a tissue can selectively promote the growth of one mast cell subtype while suppressing the other. One possible explanation could be the presence of site-specific growth factors that act differentially on newly recruited MC and MC progenitors. Although it is difficult to speculate about the biological significance of differently-sized populations, the consistency of this feature could be a useful discriminator in the further characterisation of site-specific populations. Some clues about functional roles are, however, provided by Schulman et al who reported a differential histamine release among differently-sized mast cell populations in vitro.

From a more general perspective, our discovery of site-specific mast cell subtypes supports the idea of microlocalisation as a determinant in creating differential phenotypes of infiltrating cells. Indeed, both the airways and pulmonary vessels contain sub-anatomical compartments such as smooth muscle bundles and epithelial/endothelial regions that may differentially attract and/or alter mast cell behaviour. Hence, the fact that pulmonary vessels, conducting airways and alveoli contain different proportions and types of structural cells may in part explain the present novel site-specific mast cell populations. Apart from the classical staining for tryptase and chymase, the mast cells in the present study were assessed for a variety of other mast cell-related molecules. Using this approach, we could demonstrate several statistically significant differences within each of the MC and MC categories. Some of them are intriguing, such as the reduced IgR1α and increased renin expression in the alveolar region. Others are currently difficult to assign any specific functional consequence but they nevertheless strongly support our hypothesis of site-specific mast cell populations. Importantly, for our immunohistochemical staining we used large sections that contained all anatomical compartments. This guaranteed that our comparison of molecular expression was done between anatomical regions subjected to exactly the same immunohistochemical conditions. Furthermore, electron microscopy confirmed that the mast cells were of a non-degranulated phenotype. The differences in mediator content or receptor expression are therefore not caused by differential degranulation but rather reflect distinct factors.
molecular expression at resting baseline conditions. One interpretation of this is that the unique molecular milieu in each anatomical compartment gives rise to differential mast cell priming, reflecting the different needs and functions of mast cells in various parts of the lungs.

In summary, this study shows several novel aspects of the heterogeneity of normal lung mast cells. Many of them clearly go beyond the prevailing MCT and MCTC classification. As revealed by morphological and molecular parameters, small and large airways, pulmonary vessels and the alveolar parenchyma each seem to harbour site-specific MCT and MCTC populations. Among these, the alveolar mast cell types comprised the most abundant yet most poorly studied populations. Consideration of the present expanded heterogeneity seems warranted in future studies on the physiological and pathogenic roles of mast cells in health and respiratory disease.

Acknowledgements: The authors thank Karin Jansner and Britt-Marie Nilsson for skilful technical assistance with tissue processing, immunohistochemical staining and TEM procedures, and Professor Lo Persson for kindly providing the HDC antibody.

Funding: This study was supported by grants from the Heart and Lung Foundation, Sweden, the Swedish Medical Research Council, Swedish Asthma and Allergy Association’s Research Foundation and the Crafoord Foundation.

Competing interests: None.

Ethics approval: All subjects were given written informed consent and the study was approved by the local ethics committee.

REFERENCES

Novel site-specific mast cell subpopulations in the human lung

C K Andersson, M Mori, L Bjerner, C-G Löfdahl and J S Erjefält

Thorax 2009 64: 297-305 originally published online January 8, 2009
doi: 10.1136/thx.2008.101683

Updated information and services can be found at:
http://thorax.bmj.com/content/64/4/297

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2009/03/12/64.4.297.DC1

References
This article cites 38 articles, 14 of which you can access for free at:
http://thorax.bmj.com/content/64/4/297#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/